- Giles JT, Bathon JM. Serious infections associated with anticytokine therapies in the rheumatic
diseases. J Intensive Care Med 2004; 19:320–334. - Lee JH, Slifman NR, Gershon SK, et al. Life-threatening histoplasmosis complicating immunotherapy
with tumor necrosis factor alpha antagonists infliximab and etanercept. Arthritis Rheum 2002;
46:2565–2570. - Wood KL, Hage CA, Knox KS, et al. Histoplasmosis after treatment with anti-tumor necrosis factor-
alpha therapy. Am J Respir Crit Care Med 2003; 167:1279–1282. - Wallis RS, Broder M, Wong J, et al. Reactivation of latent granulomatous infections by infliximab. Clin
Infect Dis 2005; 41(suppl 3):S194–S198. - Crum NF, Lederman ER, Wallace MR. Infections associated with tumor necrosis factor alpha
antagonists. Medicine (Baltimore) 2005; 84:291–302. - Shrestha RK, Stoller JK, Honari G, et al. Pneumonia due toCryptococcus neoformansin a patient
receiving infliximab: possible zoonotic transmission from a pet cockatiel. Respir Care 2004;
49:606–608. - Hage CA, Wood KL, Winer-Muram HT, et al. Pulmonary cryptococcosis after initiation of anti-tumor
necrosis factor-a therapy [letter]. Chest 2003; 124:2395–2397. - Arend SM, Kuijper EJ, Allaart CF, et al. Cavitating pneumonia after treatment with infliximab and
prednisone. Eur J Clin Microbiol Infect Dis 2004; 23:638–641. - True DG, Penmetcha M, Peckham SJ. Disseminated cryptococcal infection in rheumatoid arthritis
treated with methotrexate and infliximab. J Rheumatol 2002; 29:1561–1563. - Stenger AA, Houtman PM, Bruyn GA, et al.Pneumocystis cariniipneumonia associated with low dose
methotrexate treatment for rheumatoid arthritis. Scand J Rheumatol 1994; 23:51–53. - Arthritis Drugs Advisory Committee. Safety update on TNF-aantagonists: infliximab and etanercept.
Available at: http://www.fda.gov. Accessed on November 4, 2008. - Kaur N, Mahl TC.Pneumocystis jiroveci (carinii) pneumonia after infliximab therapy: a review of
84 cases. Dig Dis Sci 2007; 52(6):1481–1484. - Herbein G, O’Brien WA. Tumor necrosis factor (TNF)-alpha and TNF receptors in viral pathogenesis.
Proc Soc Exp Biol Med 2000; 223:241–257. - Minagawa H, Hashimoto K, Yanagi Y. Absence of tumour necrosis factor facilitates primary and
recurrent herpes simplex virus-1 infections. J Gen Virol 2004; 85(pt 2):343–347. - Rosandich PA, Kelley JT III, Conn DL. Perioperative management of patients with rheumatoid
arthritis in the era of biologic response modifiers. Curr Opin Rheumatol 2004; 16:192–198. - Marchal L, D’Haens G, Van Assche G, et al. The risk of post-operative complications associated with
infliximab therapy for Crohn’s disease: a controlled cohort study. Aliment Pharmacol Ther 2004;
19:749–754. - Bibbo C, Goldberg JW. Infectious and healing complications after elective orthopaedic foot and
ankle surgery during tumor necrosis factor–alpha inhibition therapy [abstr]. Foot Ankle Int 2004;
25:331–335. - den Broeder AA, Creemers MCW, Fransen J, et al. Risk factors for surgical site infections and other
complications in elective surgery in patients with rheumatoid arthritis with special attention for anti-
tumor necrosis factor: a large retrospective study. J Rheumatol 2007; 34:689–695. - Giles JT, Bartlett SJ, Gelber AC, et al. Tumor necrosis factor inhibitor therapy and risk of serious
postoperative orthopedic infection in rheumatoid arthritis. Arth Care Res 2006; 55(2):333–337. - Salliot C, Gossec L, Ruyssen-Witrand A, et al. Infections during tumour necrosis factor-ablocker
therapy for rheumatic diseases in daily practice: a systematic retrospective study of 709 patients.
Rheumatology (Oxford) 2007; 46:327–334. - Dixon WG, Watson K, Lunt M, et al. Rates of serious infection, including site-specific and bacterial
intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy.
Arthritis Rheum 2006; 54:2368–2376. - Ledingham J, Deighton C, British Society for Rheumatology Standards, Guidelines and Audit
Working Group. Update on the British Society for Rheumatology guidelines for prescribing TNF-a
blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001).
Rheumatology (Oxford) 2005; 44(2):157–163. - Saketkoo LA, Espinoza LR. Impact of biologic agents on infectious diseases. Infect Dis Clin North Am
2006; 20:931–961. - Wood AJ. Thrombotic thrombocytopenic purpura and clopidogrel: a need for new approaches to
drug safety. N Engl J Med 2000; 342:1824–1826. - Kane-Gill SL, Devlin JW. Adverse drug event reporting in intensive care units: a survey of current
practices. Ann Pharmacother 2006; 40(7–8):1267–1273. - Kremer JM. The CORRONA database. Autoimmun Rev 2006; 5:46–54.
386 Saketkoo and Espinoza